Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Micafungin.

Blair Jarvis1, David P Figgitt, Lesley J Scott

  • 1Adis International Limited, 41 Centorial Drive, Mairangi Bay, Auckland 1311, New Zealand.

Drugs
|April 23, 2004
PubMed
Summary
This summary is machine-generated.

Micafungin, an echinocandin antifungal, effectively treats Candida and Aspergillus infections by inhibiting fungal cell wall synthesis. It demonstrates efficacy and tolerability in various patient populations, including prophylaxis in stem cell transplant recipients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2022
Same author

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2021
Same author

Opicapone: A Review in Parkinson's Disease.

CNS drugs·2021
Same author

Lumasiran: First Approval.

Drugs·2021
Same author

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer.

Targeted oncology·2020
Same author

Siponimod: A Review in Secondary Progressive Multiple Sclerosis.

CNS drugs·2020
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Mycology
  • Pharmacology
  • Infectious Diseases

Background:

  • Micafungin is an echinocandin antifungal agent targeting beta-(1,3)-D-glucan synthase.
  • It exhibits broad-spectrum antifungal activity against Candida and Aspergillus species, including azole-resistant strains.

Purpose of the Study:

  • To evaluate the efficacy and safety of micafungin in treating various fungal infections.
  • To assess micafungin's effectiveness in antifungal prophylaxis.

Main Methods:

  • Clinical trials including double-blind and nonblind studies.
  • Evaluation of intravenous micafungin doses (50-150 mg/day) for oesophageal candidiasis.
  • Comparison with fluconazole for treatment and prophylaxis.

Main Results:

Related Experiment Videos

  • Micafungin eradicated oesophageal candidiasis in HIV-positive patients, with higher doses showing greater efficacy.
  • Effective treatment of invasive aspergillosis, candidiasis, and candidaemia in diverse patient groups.
  • Micafungin prophylaxis was superior to fluconazole in hematopoietic stem cell transplant recipients (80% vs. 73.5% success).

Conclusions:

  • Micafungin is an effective and well-tolerated antifungal agent for various invasive fungal infections.
  • It offers a valuable alternative to fluconazole, particularly for prophylaxis in high-risk patients.